Craig Hallum Forecasts Strong Price Appreciation for Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma (NASDAQ:XERS) had its price target raised by equities research analysts at Craig Hallum from $5.00 to $6.50 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Craig Hallum’s price objective would suggest a potential upside of 53.30% from the stock’s previous close.

XERS has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research note on Friday. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research report on Friday. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.90.

Xeris Biopharma Stock Up 2.7 %

NASDAQ:XERS opened at $4.24 on Friday. The firm has a market capitalization of $632.10 million, a P/E ratio of -9.42 and a beta of 2.32. Xeris Biopharma has a twelve month low of $1.69 and a twelve month high of $4.50. The company has a fifty day moving average of $3.57 and a 200-day moving average of $3.26.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC bought a new stake in Xeris Biopharma during the 4th quarter worth approximately $34,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Xeris Biopharma during the third quarter valued at approximately $35,000. R Squared Ltd bought a new stake in Xeris Biopharma during the fourth quarter worth $42,000. Quantbot Technologies LP purchased a new stake in Xeris Biopharma in the 3rd quarter valued at $44,000. Finally, Cibc World Markets Corp bought a new position in Xeris Biopharma during the 4th quarter valued at $44,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.